Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the average analyst EPS estimate compiled by FactSet of $2.68.

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68. The pharmaceutical giant reported sales of $23.

Johnson & Johnson ( NYSE: JNJ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET

C.J. Gardner-Johnson said he "retracts" the comments he made about the Philadelphia Eagles after he was traded to the Houston Texans this offseason, when he said the team "probably won't see a ring without me.

In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its popular immune system medicine Stelara, which is facing a patent cliff. Sales in its smaller, medtech division increased 6 per cent.

Johnson shared yet another personal insight that nobody asked for: His jizz has substantially more microplastics in it than his blood does. On X on Tuesday, Johnson posted: “I have microplastics in my ejaculate.

The third-term Democrat from Dallas faces long odds in a state that has only elected Republicans to statewide office for three decades.

Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.